chemotherapy treatment called GPOH

Phase 1Small molecule

PPrincess Maxima Center for Pediatric Oncology

chemotherapy treatment called GPOH is one of 53 small molecule programs targeting Neuroblastoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeuroblastomaRecruiting

NeuroblastomaPhase 1

Recruiting

Competition

Competitive Landscape

88 competitors in Neuroblastoma

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

52 2

Vepesid

AAvyxa

Phase 3

40 3

Paraplatin

AAvyxa

Phase 3

35 4

Leukine

Sanofi

Phase 3

15 5

Camptosar

Pfizer

Phase 3

12 6

Tepadina

Jazz Pharmaceuticals

Phase 3

11 7

Alkeran

AApotex Inc.

Phase 3

28 8

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

26 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Adriamycin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 1Recruiting

Neuroblastoma

NCT06485947

Clinical

Trials by Indication[1]

Neuroblastoma1 trial

Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma

Recruiting·PPrincess Maxima Center for Pediatric Oncology·Phase 1·NCT06485947·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for chemotherapy treatment called GPOH. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — chemotherapy treatment called GPOH compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for chemotherapy treatment called GPOH. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Princess Maxima Center for Pediatric Oncology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPrincess Maxima Center for Pediatric Oncology

chemotherapy treatment called GPOH

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Neuroblastoma1 trial

References

Drug Info

Quick Facts

Related News